[
  {
    "ts": "2026-02-26T11:11:30+00:00",
    "headline": "How The Edwards Lifesciences (EW) Investment Story Is Shifting After Mixed Analyst Revisions",
    "summary": "Edwards Lifesciences is working with a slightly lower fair value estimate, trimmed from US$97.11 to US$96.46 per share, which puts a finer point on how analysts are thinking about the stock today. That small shift lines up with a mix of optimism and caution in recent research, where some analysts are raising price targets while others are scaling them back in light of execution and competitive risks. As you read on, you will see how these moving targets fit into the broader story and what to...",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-investment-story-111130263.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2b4cb796-7e5a-3819-94c1-4149db2d23e3",
      "content": {
        "id": "2b4cb796-7e5a-3819-94c1-4149db2d23e3",
        "contentType": "STORY",
        "title": "How The Edwards Lifesciences (EW) Investment Story Is Shifting After Mixed Analyst Revisions",
        "description": "",
        "summary": "Edwards Lifesciences is working with a slightly lower fair value estimate, trimmed from US$97.11 to US$96.46 per share, which puts a finer point on how analysts are thinking about the stock today. That small shift lines up with a mix of optimism and caution in recent research, where some analysts are raising price targets while others are scaling them back in light of execution and competitive risks. As you read on, you will see how these moving targets fit into the broader story and what to...",
        "pubDate": "2026-02-26T11:11:30Z",
        "displayTime": "2026-02-26T11:11:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-investment-story-111130263.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-investment-story-111130263.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]